Literature DB >> 24009077

Factor VIII C1 domain spikes 2092-2093 and 2158-2159 comprise regions that modulate cofactor function and cellular uptake.

Esther Bloem1, Maartje van den Biggelaar, Aleksandra Wroblewska, Jan Voorberg, Johan H Faber, Marianne Kjalke, Henning R Stennicke, Koen Mertens, Alexander B Meijer.   

Abstract

The C1 domain of factor VIII (FVIII) has been implicated in binding to multiple constituents, including phospholipids, von Willebrand factor, and low-density lipoprotein receptor-related protein (LRP). We have previously described a human monoclonal antibody called KM33 that blocks these interactions as well as cellular uptake by LRP-expressing cells. To unambiguously identify the apparent "hot spot" on FVIII to which this antibody binds, we have employed hydrogen-deuterium exchange mass spectrometry. The results showed that KM33 protects FVIII regions 2091-2104 and 2157-2162 from hydrogen-deuterium exchange. These comprise the two C1 domain spikes 2092-2093 and 2158-2159. Spike 2092-2093 has been demonstrated recently to contribute to assembly with lipid membranes with low phosphatidylserine (PS) content. Therefore, spike 2158-2159 might serve a similar role. This was assessed by replacement of Arg-2159 for Asn, which introduces a motif for N-linked glycosylation. Binding studies revealed that the purified, glycosylated R2159N variant had lost its interaction with antibody KM33 but retained substantial binding to von Willebrand factor and LRP. Cellular uptake of the R2159N variant was reduced both by LRP-expressing U87-MG cells and by human monocyte-derived dendritic cells. FVIII activity was virtually normal on membranes containing 15% PS but reduced at low PS content. These findings suggest that the C1 domain spikes 2092-2093 and 2158-2159 together modulate FVIII membrane assembly by a subtle, PS-dependent mechanism. These findings contribute evidence in favor of an increasingly important role of the C1 domain in FVIII biology.

Entities:  

Keywords:  Endocytosis; Enzyme Kinetics; Epitope Mapping; Factor VIII; Mass Spectrometry (MS); Phospholipid; Surface Plasmon Resonance (SPR); von Willebrand Factor

Mesh:

Substances:

Year:  2013        PMID: 24009077      PMCID: PMC3795264          DOI: 10.1074/jbc.M113.473116

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

Review 1.  Hydrogen exchange mass spectrometry for the analysis of protein dynamics.

Authors:  Thomas E Wales; John R Engen
Journal:  Mass Spectrom Rev       Date:  2006 Jan-Feb       Impact factor: 10.946

2.  The interface between the EGF2 domain and the protease domain in blood coagulation factor IX contributes to factor VIII binding and factor X activation.

Authors:  Caroline Fribourg; Alexander B Meijer; Koen Mertens
Journal:  Biochemistry       Date:  2006-09-05       Impact factor: 3.162

Review 3.  Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates.

Authors:  I Scharrer; G L Bray; O Neutzling
Journal:  Haemophilia       Date:  1999-05       Impact factor: 4.287

4.  Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain.

Authors:  Eszter Herczenik; Simon D van Haren; Aleksandra Wroblewska; Paul Kaijen; Maartje van den Biggelaar; Alexander B Meijer; Luisa Martinez-Pomares; Anja ten Brinke; Jan Voorberg
Journal:  J Allergy Clin Immunol       Date:  2011-10-01       Impact factor: 10.793

5.  LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo.

Authors:  Niels Bovenschen; Koen Mertens; Lihui Hu; Louis M Havekes; Bart J M van Vlijmen
Journal:  Blood       Date:  2005-04-19       Impact factor: 22.113

6.  Partial glycosylation of Asn2181 in human factor V as a cause of molecular and functional heterogeneity. Modulation of glycosylation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation.

Authors:  G A Nicolaes; B O Villoutreix; B Dahlbäck
Journal:  Biochemistry       Date:  1999-10-12       Impact factor: 3.162

7.  Partial glycosylation at asparagine-2181 of the second C-type domain of human factor V modulates assembly of the prothrombinase complex.

Authors:  S W Kim; T L Ortel; M A Quinn-Allen; L Yoo; L Worfolk; X Zhai; B R Lentz; W H Kane
Journal:  Biochemistry       Date:  1999-08-31       Impact factor: 3.162

8.  Requirements for cellular co-trafficking of factor VIII and von Willebrand factor to Weibel-Palade bodies.

Authors:  M van den Biggelaar; R Bierings; G Storm; J Voorberg; K Mertens
Journal:  J Thromb Haemost       Date:  2007-11       Impact factor: 5.824

9.  The tertiary structure and domain organization of coagulation factor VIII.

Authors:  Betty W Shen; Paul Clint Spiegel; Chong-Hwan Chang; Jae-Wook Huh; Jung-Sik Lee; Jeanman Kim; Young-Ho Kim; Barry L Stoddard
Journal:  Blood       Date:  2007-10-26       Impact factor: 22.113

10.  Functional duplication of ligand-binding domains within low-density lipoprotein receptor-related protein for interaction with receptor associated protein, alpha2-macroglobulin, factor IXa and factor VIII.

Authors:  Alexander B Meijer; Jakub Rohlena; Carmen van der Zwaan; Anton-Jan van Zonneveld; Ria C Boertjes; Peter J Lenting; Koen Mertens
Journal:  Biochim Biophys Acta       Date:  2007-04-14
View more
  20 in total

1.  Factor VIII Interacts with the Endocytic Receptor Low-density Lipoprotein Receptor-related Protein 1 via an Extended Surface Comprising "Hot-Spot" Lysine Residues.

Authors:  Maartje van den Biggelaar; Jesper J Madsen; Johan H Faber; Marleen G Zuurveld; Carmen van der Zwaan; Ole H Olsen; Henning R Stennicke; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2015-04-21       Impact factor: 5.157

2.  The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells.

Authors:  Bagirath Gangadharan; Mathieu Ing; Sandrine Delignat; Ivan Peyron; Maud Teyssandier; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

3.  Inhibitory antibodies against factor VIII C1 domain.

Authors:  Gary E Gilbert
Journal:  Blood       Date:  2016-10-20       Impact factor: 22.113

Review 4.  Current approaches to fine mapping of antigen-antibody interactions.

Authors:  W Mark Abbott; Melissa M Damschroder; David C Lowe
Journal:  Immunology       Date:  2014-08       Impact factor: 7.397

5.  Evidence That Factor VIII Forms a Bivalent Complex with the Low Density Lipoprotein (LDL) Receptor-related Protein 1 (LRP1): IDENTIFICATION OF CLUSTER IV ON LRP1 AS THE MAJOR BINDING SITE.

Authors:  Patricia A Young; Mary Migliorini; Dudley K Strickland
Journal:  J Biol Chem       Date:  2016-10-29       Impact factor: 5.157

6.  Molecular mechanisms of missense mutations that generate ectopic N-glycosylation sites in coagulation factor VIII.

Authors:  Wei Wei; Saurav Misra; Matthew V Cannon; Renchi Yang; Xiaofan Zhu; Reid Gilmore; Min Zhu; Bin Zhang
Journal:  Biochem J       Date:  2018-03-06       Impact factor: 3.857

7.  Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry.

Authors:  Po-Lin Chiu; George M Bou-Assaf; Ekta Seth Chhabra; Melissa G Chambers; Robert T Peters; John D Kulman; Thomas Walz
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

8.  Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products.

Authors:  Wojciech Jankowski; Yara Park; Joseph McGill; Eugene Maraskovsky; Marco Hofmann; Vincent P Diego; Bernadette W Luu; Tom E Howard; Roberta Kellerman; Nigel S Key; Zuben E Sauna
Journal:  Blood Adv       Date:  2019-05-14

9.  Membrane Interaction of the Factor VIIIa Discoidin Domains in Atomistic Detail.

Authors:  Jesper J Madsen; Y Zenmei Ohkubo; Günther H Peters; Johan H Faber; Emad Tajkhorshid; Ole H Olsen
Journal:  Biochemistry       Date:  2015-09-30       Impact factor: 3.162

10.  High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.

Authors:  Glaivy Batsuli; Wei Deng; John F Healey; Ernest T Parker; W Hunter Baldwin; Courtney Cox; Brenda Nguyen; Joerg Kahle; Christoph Königs; Renhao Li; Pete Lollar; Shannon L Meeks
Journal:  Blood       Date:  2016-07-05       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.